Johnson & Johnson (JNJ) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability Durable ⢠Cash Flow Support ⢠Leverage Rising Johnson & Johnson shows durable profitability and cash generation that supports its dividend, but thin liquidity, rising leverage, heavy intangibles, and a rich valuation limit near-term appeal.
Price Behavior
Key Price Behavior Insights: ⢠Trend intact ⢠233 resistance ⢠223 support Support Level: $223-$225 Resistance Level: $233 JNJ's price action over the last month is modestly constructive, with a rebound off the June 2 low back above $230, but it still needs a clean break above $233 to confirm upside while $223-$225 remains the key support zone.
Sentiment & News
Key News Insights: ⢠Growth Momentum ⢠Legal Pressure ⢠Mixed Sentiment Johnson & Johnson's news flow shows solid growth catalysts from oncology, MedTech and pipeline progress, but ongoing patent, talc, China and valuation concerns keep sentiment cautious.
AI Summary
JNJ now looks less like a sleepy dividend hold and more like a re-accelerating pharma story, but the stock only works here if non-STELARA growth keeps compounding fast enough to offset STELARA erosion and legal/China headwinds at a still-premium valuation.
Description
Johnson & Johnson develops, manufactures and sells healthcare products worldwide through three principal businesses: Consumer Health, Pharmaceuticals and MedTech. Its Consumer Health unit offers household personal-care and over-the-counter medicines, the Pharmaceuticals division markets prescription therapies across immunology, infectious disease, CNS, oncology, cardiovascular and metabolic indications, and the MedTech business supplies devices for cardiovascular, neurovascular, orthopaedic, surgical and vision care. The company distributes to retailers, wholesalers, hospitals and healthcare professionals and is headquartered in New Brunswick, New Jersey; it was founded in 1886.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 23 | Jan 30 | JNJ | Johnson & Johnson | Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026. | Closed | +3.2% |
| Nov 17 | Nov 24 | JNJ | Johnson & Johnson | Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup. | Closed | +3.2% |